Try Fund Library Premium
Free with a 30 day trial!
Gain access to
- Unlimited Watchlists
- Advanced Search Filtering
- Fund Comparisons
- Portfolio Scenarios
- Customizable PDF Reports
- Portfolio Rebalancer new
Portland Life Sciences Alternative Fund Series A
Alternative Equity Focus
Click for more information on Fundata’s FundGrade
FundGrade D
Click for more information on Fundata’s FundGrade.
FundGrade A+® Rating Recipient
2024
Click for more information on Fundata’s FundGrade
|
NAVPS (06-19-2026) |
$14.59 |
|---|---|
| Change |
$0.05
(0.34%)
|
As at May 31, 2026
As at May 31, 2026
Loading......
Legend
Compare Options
Fund Returns
Inception Return (April 14, 2021): 8.07%
| Row Heading | Return | Annualized Return | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 Mth | 3 Mth | 6 Mth | YTD | 1 Yr | 2 Yr | 3 Yr | 4 Yr | 5 Yr | 6 Yr | 7 Yr | 8 Yr | 9 Yr | 10 Yr | |
| Fund | 0.42% | -8.17% | -9.76% | -1.74% | 10.93% | -9.48% | 8.31% | 12.90% | 8.27% | - | - | - | - | - |
| Benchmark | 2.52% | 1.83% | 12.07% | 10.61% | 36.06% | 28.34% | 24.64% | 17.23% | 15.30% | 18.20% | 15.06% | 13.48% | 12.83% | 12.77% |
| Category Average | 2.82% | 4.37% | 9.17% | 9.21% | 23.49% | 15.75% | 16.26% | 11.26% | 9.16% | 11.53% | 9.52% | - | - | - |
| Category Rank | 180 / 258 | 243 / 255 | 240 / 243 | 219 / 245 | 158 / 218 | 167 / 167 | 95 / 126 | 44 / 117 | 45 / 88 | - | - | - | - | - |
| Quartile Ranking | 3 | 4 | 4 | 4 | 3 | 4 | 4 | 2 | 3 | - | - | - | - | - |
Monthly Return
| Return % | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Jan | Feb | Mar | Apr | May |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fund | 2.98% | 12.28% | -12.73% | 8.40% | 8.57% | 3.52% | -8.16% | 0.76% | 6.19% | -7.84% | -0.78% | 0.42% |
| Benchmark | 2.91% | 1.69% | 4.96% | 5.40% | 0.97% | 3.86% | 1.32% | 0.84% | 7.72% | -4.32% | 3.81% | 2.52% |
Best Monthly Return Since Inception
14.43% (May 2024)
Worst Monthly Return Since Inception
-12.78% (December 2024)
Calendar Return (%)
| Return % | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Fund | - | - | - | - | - | - | -1.20% | 30.77% | 26.13% | -9.64% |
| Benchmark | 21.08% | 9.10% | -8.89% | 22.88% | 5.60% | 25.09% | -5.84% | 11.75% | 21.65% | 31.68% |
| Category Average | - | - | - | - | 5.11% | 17.27% | -5.96% | 6.54% | 16.58% | 15.40% |
| Quartile Ranking | - | - | - | - | - | - | 2 | 1 | 2 | 4 |
| Category Rank | - | - | - | - | - | - | 31/ 105 | 13/ 121 | 45/ 142 | 194/ 194 |
Best Calendar Return (Last 10 years)
30.77% (2023)
Worst Calendar Return (Last 10 years)
-9.64% (2025)
Asset Allocation
| Name | Percent |
|---|---|
| US Equity | 56.15 |
| International Equity | 41.19 |
| Cash and Equivalents | 2.67 |
Sector Allocation
| Name | Percent |
|---|---|
| Healthcare | 96.01 |
| Cash and Cash Equivalent | 2.66 |
| Technology | 1.33 |
Geographic Allocation
| Name | Percent |
|---|---|
| North America | 58.78 |
| Asia | 35.69 |
| Europe | 5.53 |
Top Holdings
| Name | Percent |
|---|---|
| Lantheus Holdings Inc | 15.61 |
| Telix Pharmaceuticals Ltd | 14.29 |
| Clarity Pharmaceuticals Ltd | 13.87 |
| Perspective Therapeutics Inc | 8.60 |
| Beigene Ltd - ADR | 7.54 |
| RadNet Inc | 5.82 |
| Olema Pharmaceuticals Inc | 5.76 |
| Danaher Corp | 4.79 |
| Iovance Biotherapeutics Inc | 4.65 |
| Amgen Inc | 4.44 |
Equity Style
Fixed Income Style
Risk vs Return (3 Yr)
Portland Life Sciences Alternative Fund Series A
Median
Other - Alternative Equity Focus
3 Yr Annualized
| Standard Deviation | 25.04% | 21.25% | - |
|---|---|---|---|
| Beta | 0.94 | 0.67 | - |
| Alpha | -0.10 | 0.00 | - |
| Rsquared | 0.16% | 0.16% | - |
| Sharpe | 0.30 | 0.34 | - |
| Sortino | 0.48 | 0.52 | - |
| Treynor | 0.08 | 0.11 | - |
| Tax Efficiency | 100.00% | - | - |
| Volatility |
|
|
- |
Risk Rating
Annualized Key Ratio Period Comparison
| Key Ratio | 1 Yr | 3 Yr | 5 Yr | 10 Yr |
|---|---|---|---|---|
| Standard Deviation | 26.22% | 25.04% | 21.25% | - |
| Beta | 0.68 | 0.94 | 0.67 | - |
| Alpha | -0.08 | -0.10 | 0.00 | - |
| Rsquared | 0.07% | 0.16% | 0.16% | - |
| Sharpe | 0.43 | 0.30 | 0.34 | - |
| Sortino | 0.61 | 0.48 | 0.52 | - |
| Treynor | 0.17 | 0.08 | 0.11 | - |
| Tax Efficiency | 100.00% | 100.00% | - | - |
Fund Details
| Start Date | April 14, 2021 |
|---|---|
| Instrument Type | Mutual Fund (Alternative) |
| Share Class | Commission Based Advice |
| Legal Status | Trust |
| Sales Status | Open |
| Currency | CAD |
| Distribution Frequency | Annual |
| Assets ($mil) | $16 |
Fund Codes
| FundServ Code | Load Code | Sales Status |
|---|---|---|
| PTL320 | ||
| PTL325 | ||
| PTL330 |
Investment Objectives
The Fund’s objective is to provide positive long-term total returns by investing primarily in a portfolio of securities focused on companies active in the healthcare sector. The Fund may also engage in borrowing for investment purposes. The Fund’s aggregate exposure shall not exceed limits on the use of gross exposure or as otherwise permitted under applicable securities legislation.
Investment Strategy
The Fund seeks to provide capital growth by primarily investing in a portfolio of equities, ADRs and may also invest in ETFs. The Fund’s investments currently focus on the area of precision oncology. The Fund also may invest in income trusts, debt securities convertible into common stock, convertible and non-convertible preferred stock, debt-like securities and fixed/floating income securities of governments, government agencies, supranational agencies, companies, trusts and limited partnerships
Portfolio Management
| Portfolio Manager |
Portland Investment Counsel Inc.
|
|---|---|
| Sub-Advisor |
- |
Management and Organization
| Fund Manager |
Portland Investment Counsel Inc. |
|---|---|
| Custodian |
CIBC Mellon Trust Company |
| Registrar |
CIBC Mellon Global Securities Services Company |
| Distributor |
Mandeville Private Client Inc. |
Investment Minimums
| RSP Eligible | Yes |
|---|---|
| PAC Allowed | Yes |
| PAC Initial Investment | 50 |
| PAC Subsequent | 50 |
| SWP Allowed | Yes |
| SWP Min Balance | 5,000 |
| SWP Min Withdrawal | 50 |
Fees
| MER | 2.53% |
|---|---|
| Management Fee | 1.75% |
| Load | Choice of Front or No Load |
| FE Max | 6.00% |
| DSC Max | - |
| Trailer Fee Max (FE) | 1.00% |
| Trailer Fee Max (DSC) | 1.00% |
| Trailer Fee Max (NL) | - |
| Trailer Fee Max (LL) | - |
Try Fund Library Premium
Free with a 30 day trial!
Gain access to
- Unlimited Watchlists
- Advanced Search Filtering
- Fund Comparisons
- Portfolio Scenarios
- Customizable PDF Reports
- Portfolio Rebalancer new
